Last $123.52 USD
Change Today -1.45 / -1.16%
Volume 1.1M
PCYC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PCYC) Key Developments

Pharmacyclics Inc. Wins $3.8 Billion Contract from Department of Veterans Affairs

Pharmacyclics Inc. was awarded a $3.8 billion contract by the Department of Veterans Affairs for its Imbruvica drug.

Pharmacyclics Appoints Shawn Cline Tomasello as Chief Commercial Officer

Pharmacyclics Inc. appointed Shawn Cline Tomasello as its Chief Commercial Officer. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan(R) at Genentech.

Pharmacyclics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Pharmacyclics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenue was $113,020,000 against $54,684,000 a year ago. Loss from operations was $37,204,000 against income of $12,031,000 a year ago. Loss before income taxes was $37,238,000 against income of $12,008,000 a year ago. Net loss was $37,057,000 or $0.49 basic and diluted per share against income of $12,351,000 or $0.16 diluted per share a year ago. Non-GAAP net loss was $19,712,000 or $0.26 basic and diluted per share against income of $19,212,000 or $0.49 diluted per share a year ago. For the six months, the company's total revenue was $232,397,000 against $57,530,000 a year ago. Loss from operations was $18,979,000 against $40,933,000 a year ago. Loss before income taxes was $18,975,000 against $40,877,000 a year ago. Net loss was $18,782,000 or $0.25 basic and diluted per share against $39,560,000 or $0.55 basic and diluted per share a year ago. Non-GAAP net income was $11,549,000 or $0.15 basic and diluted per share against loss of $9,121,000 or $0.13 basic and diluted per share a year ago.

Pharmacyclics Inc., Q2 2014 Earnings Call, Jul 31, 2014

Pharmacyclics Inc., Q2 2014 Earnings Call, Jul 31, 2014

Pharmacyclics Inc. - Special Call

To discuss approval of IMBRUVICA for the treatment of patients with chronic lymphocytic leukemia

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCYC:US $123.52 USD -1.45

PCYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celgene Corp $93.85 USD +0.58
View Industry Companies
 

Industry Analysis

PCYC

Industry Average

Valuation PCYC Industry Range
Price/Earnings 100.0x
Price/Sales 21.3x
Price/Book 14.2x
Price/Cash Flow 105.7x
TEV/Sales 19.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.